• Shannon Armbruster, Robert L Coleman, and Jose Alejandro Rauh-Hain.
• Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030-1362, USA.
• Hematol. Oncol. Clin. North Am. 2018 Dec 1; 32 (6): 965-982.

AbstractMost women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The role of secondary cytoreduction remains a topic of active investigation.Copyright © 2018 Elsevier Inc. All rights reserved.

27 keywords...

hide…